Home > News > Natco Pharma recalls breast cancer drug
July 18th, 2009
Natco Pharma recalls breast cancer drug
Abstract:
Natco Pharma Ltd has recalled its breast cancer drug Albupax following an order from the Drug Controller General of India (DCGI), which said that the drug might cause damage to liver.
The Hyderabad-based company has stopped the production, distribution and marketing of the drug and is in the process of recalling stocks, a company spokesperson told Business Line.
"The product has passed all quality tests. However, on DCGI's instructions, we have stopped marketing the product in the interim.
"We are taking immediate steps to investigate the issue," he said.
Testing procedures
The testing procedures for the drug should also be looked into as Albupax was nanotechnology-based products.
"The testing procedures for this drug are quite complex," he added.
Natco is currently engaged in a legal dispute on patent of Albupax with its original innovator, American Biosciences and is awaiting judgment.
Source:
thehindubusinessline.com
Bookmark:
| Related News Press |
News and information
Enhancing power factor of p- and n-type single-walled carbon nanotubes April 25th, 2025
Tumor microenvironment dynamics: the regulatory influence of long non-coding RNAs April 25th, 2025
Ultrafast plasmon-enhanced magnetic bit switching at the nanoscale April 25th, 2025
Nanomedicine
Tumor microenvironment dynamics: the regulatory influence of long non-coding RNAs April 25th, 2025
Next-generation drug delivery innovation! DGIST develops precision therapeutics using exosomes April 25th, 2025
Multiphoton polymerization: A promising technology for precision medicine February 28th, 2025
Rice researchers harness gravity to create low-cost device for rapid cell analysis February 28th, 2025
Announcements
Enhancing power factor of p- and n-type single-walled carbon nanotubes April 25th, 2025
Tumor microenvironment dynamics: the regulatory influence of long non-coding RNAs April 25th, 2025
Ultrafast plasmon-enhanced magnetic bit switching at the nanoscale April 25th, 2025
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||